Amgen Inc. and Allergan Inc. have filed their biosimilar version of Roche’s anticancer Avastin (bevacizumab), ABP 215, with the European Medicines Agency for the treatment of non-small cell lung cancer, targeting another hefty portion of an originator molecule market that reached almost $7bn in 2016.
Announced on Dec. 2, this is the second major filing for ABP 215 in the space of just over two...







